Short-term renal and cardiac outcomes of combined ARNI and SGLT2 therapy in AHF patients: a prospective single-arm interventional study
-
By
-
May 1, 2026
Objective:
To explore changes in diuretic and renal outcomes following initiation of combined ARNI and SGLT2 inhibitors therapy in patients with acute heart failure, specifically focusing on the effects on urine volume and renal function.
Key Findings:
- Urine volume and diuretic response increased significantly on day 1, stabilizing above baseline levels, with p-values reported.
- Cardiovascular biomarkers showed improvements, with decreased NT-proBNP and increased LVEF, indicating clinical significance.
- eGFR remained unaffected during the combination therapy, suggesting safety in renal function.
Interpretation:
The findings suggest that combined ARNI and SGLT2 inhibitor therapy may enhance diuresis and improve cardiac function in AHF patients, warranting further investigation through randomized controlled trials to confirm these results and explore long-term outcomes.
Limitations:
- Short-term nature of the study limits the ability to assess long-term effects.
- Lack of a control group restricts causal attribution of observed effects, necessitating caution in interpretation.
Conclusion:
The study supports the potential clinical utility of ARNI and SGLT2 inhibitors in managing acute heart failure, highlighting the need for further research to validate these findings and explore their implications for clinical practice.
